The Canadian government has authorized a startup to ship psychedelic substances to Australia for therapeutic purposes. Optimi Health Corp. is responsible for distributing pills laced with psilocybin, an ingredient found in magic mushrooms, and MDMA, as sanctioned by the health department.
The increasing demand goes beyond the local magic mushrooms Ontario. Other countries are following suit, starting to explore and sanction the use of serotogenic substances for medicinal reasons.
You can buy psychedelics online in Canada with confidence and tap into your inherent potential through trusted sources.
[toc]Main Takeaways:
- Vancouver-based startup, Optimi Health, has secured a drug establishment license to export magic mushroom pills to Australia.
- Australia allows licensed psychiatrists to use magic mushrooms for treating persistent depression.
- The treatment comprises three sessions over five to eight weeks, with each session spanning about eight hours.
Rise of Psilocybin Capsules in Canada
Optimi, a startup based in Vancouver, aims to use its certification to broaden the pharmaceutical landscape for psychedelic drugs and gain a head start in the market.
Seven firms have exported psilocybin, MDMA, or both, but only for clinical trials. A spokesperson from Canada’s health department couldn’t confirm if these exports were for regular patient use and chose not to reveal the companies due to privacy concerns.
This achievement places Optimi amongst a handful of global suppliers, with the market currently favoring clinical over recreational use.
What’s in the Pill?
While the company hasn’t detailed the specific mushroom strain used in the pill, they work with a range of strains including Albino Penis Envy, among others.
Optimi has established a 20,000-square-foot facility in Princeton, British Columbia, to cultivate, examine, and extract its psychedelic mushrooms. This quaint community, home to roughly 3,000 inhabitants, is situated a three-hour drive east of Vancouver.
Australia’s Relationship with Psychedelic Mushrooms
Mental illness is predicted to affect 1 in 5 Australians aged between 16 and 85. Post-traumatic stress disorder (PTSD) is expected to impact 11% of Australians at some point in their lives, while anxiety disorders are common in 17% of the population.
A variety of methods exist to treat mental illnesses, but not all are effective for each individual. Those who don’t respond to certain treatments can find it difficult to identify an effective strategy, thereby amplifying their vulnerability.
Understanding the Process
Australia has been a trailblazer in the use of psilocybin, allowing licensed psychiatrists to apply this controlled substance in treating PTSD and depression resistant to conventional treatments.
In an unexpected move in February, Australia’s Therapeutic Goods Administration (TGA) reclassified MDMA and mushrooms for therapeutic use. The TGA confirmed these substances are safe when used in a medically supervised environment for patients with severe mental disorders.
This change has been revolutionary for many mental health professionals and researchers. The usage of these substances will be strictly monitored; it’s not as straightforward as taking a pill and going.
The usual treatment plan consists of three sessions spread over five to eight weeks. Each session lasts about eight hours, with the therapist staying with the patient for the entire duration.
Canada’s Role in Psilocybin Research
Canada has risen as a significant center for psilocybin research, considerably expanding our understanding of this compound. Health Canada, along with several institutions, leads the way in investigating the therapeutic potential of psilocybin for various mental health disorders.
Research institutions no longer need to label these substances as illegal or rely on unsanctioned dispensaries or mushroom shops. The government now permits certain institutions to grow mushrooms for research purposes.
The increased access to substances previously deemed harmful allows researchers to deepen their understanding of their potential benefits to many individuals.
A Recurring Developments
The potential of psychedelics as a tool for addressing mental health issues and substance dependencies was first acknowledged in the 1950s. It was English psychiatrist Humphry Osmond and Canadian biochemist Abram Hoffer who spearheaded the initial research at Weyburn The Saskatchewan Mental Hospital. The institution saw significant progress during the tenure of then-premier Tommy Douglas, who gave the medical community considerable freedom to explore their medical hypotheses.
Dr. Osmond and Dr. Hoffer began investigating LSD, mescaline, and peyote as potential alternatives to the harsh treatments of electroshock and lobotomy. Their research took unexpected turns, with the pair advocating for medical professionals and support staff to experiment with these substances.
Research at Canadian Health Institutes
Through its Institute of Neurosciences, Mental Health and Addiction, the Canadian Institutes of Health Research is sponsoring three clinical trials. These trials aim to examine the therapeutic efficacy and safety of psilocybin-assisted psychotherapy:
| Project Type | Study Focus | Research Institution | Lead Investigator | Project Budget |
| A randomized controlled trial | Psychological distress in terminally ill cancer patients | University of Toronto | Sarah Hales | $928,643 |
| Investigation of mechanisms supporting psilocybin psychotherapy for alcohol use disorder | Alcohol use disorder | University of Calgary | Leah Mayo | $1,000,000 |
| A randomized phase II clinical trial contrasting single versus dual psychedelic doses | Treatment-resistant depression | University of Toronto | Joshua Rosenblat | $1,000,000 |
This financial support for research will enable a more in-depth understanding of the advantages of controlled substances. The Canadian Drugs and Substances Strategy (CDSS), initiated by the Government of Canada, made this funding possible.
Further Psychedelic Research
Psychiatrists in Vancouver have initiated a phase III clinical trial of MDMA, commonly known as ecstasy, for treating post-traumatic stress disorder (PTSD). The protocol involves three eight-hour sessions with MDMA, spaced a month apart, alongside nine 90-minute sessions without the drug. This trial holds historical significance as it marks the first clinical exploration of an illegal substance.
It’s been over four decades since the last psychedelic substance discovery.
Getting to Know Psilocybin
Psilocybin, a naturally occurring psychedelic compound, is present in certain species of mushrooms. Once ingested, it converts into psilocin. The psilocin then stimulates serotonin 5-HT2a receptors found on the cortical pyramidal cells in the brain—these cells act as the main processing sites.
Local authorities are examining the substance for its potential to help with depression, anxiety, addiction, and distress at life’s end by promoting introspection and spiritual growth.
Why is it Effective Against Depression, PTSD, and More?
By targeting various areas of the brain, the active component proves beneficial for multiple mental disorders. Many patients in Canada and Australia have already undergone this treatment, and the results are promising, with modest side effects such as short-term anxiety or elevated blood pressure.
Effects on Neurobiology
- Activation of Serotonin Receptors: This compound serves as a partial agonist for serotonin receptors, especially the 5-HT2A subtype, which is instrumental in mood regulation and emotional processing.
- Adjustment of the Default Mode Network (DMN): It reduces DMN activity, promoting introspection, easing rigid thought patterns, and enhancing emotional adaptability.
- Stimulation of Prefrontal and Limbic Areas: The antidepressant effects of the compound result from its influence on the prefrontal and limbic regions of the brain, including the amygdala. Depressed individuals often display reduced reactivity to emotional stimuli. The compound intensifies the response to positive emotional stimuli in the right amygdala while reducing or normalizing the response to negative or neutral emotional stimuli.
Psychological and Emotional Effects:
- Promotion of Positive Mood States: It induces feelings of euphoria, interconnectedness, and emotional openness during and following the experience.
- Heightened Emotional Processing: The psychedelic experience might allow individuals to confront and process deep-seated emotions, traumatic memories, or existential concerns in a safe setting.
- Spiritual and Existential Insights: Studies from Johns Hopkins University and Imperial College London suggests that it can contribute to enduring positive changes, such as better overall happiness, increased satisfaction in life, and spiritual growth.
What Can You Discover at Your Neighborhood Magic Mushroom Shops?
Interested in how this substance could impact your mental state? You can explore local magic mushroom stores to find a product that fits your requirements.
| Product | Quantity | Potency | Benefits |
| Evoke – Medicinal Mushrooms | 20 | 100mg or 200mg | Improves mood, incites creative thinking, and enhances focus and productivity |
| Ground Sounds – Microdose Capsules – Super Freak | 30 | 50mg, 100mg, and 250mg | Boosts well-being and enriches overall quality of life |
| Kind Stranger – Microdose Capsules – Sidekick | 30 | 100mg | Provokes clarity, creativity, and concentration. Contains a potent mix of clinical strength adaptogenic herbs |
| Osmosis – Brain Boost | 30 | 100mg or 200mg | Provides cognitive and energy benefits |
Worldwide Acceptance of Psilocybin
Canada is not the sole country endorsing the utilization of magic mushrooms for mental health problems. Countries like Australia are also embracing these hallucinogens to tackle issues such as depression and PTSD. They procure superior quality psychedelic capsules from trustworthy sources. With suitable supervision, patients can significantly elevate their lifestyle. Shroomland Canada, a magic mushroom supplier, offers a wide array of products, from pills to LSD edibles.
Frequently Posed Queries
How do psilocybin and MDMA compare?
Both psilocybin and MDMA hold therapeutic potential by enhancing mental health. Psilocybin interacts with serotonin 2A receptors and is helpful in addressing depression and addiction.
Conversely, MDMA promotes empathy and proves beneficial in PTSD treatment. It demonstrates potential in improving emotional processing and
Despite being classified as a controlled substance, it offers potential therapeutic benefits.
Is this treatment option accessible to all Australians?
In Australia, not everyone can access this treatment. Individuals must undergo an assessment to ascertain their eligibility to use the substance. The evaluation takes into account factors such as existing heart conditions and history of psychosis, among others. This treatment is exclusively for patients who have not found relief from conventional treatments for conditions like depression, anxiety, or PTSD.
What are the implications of Canada exporting mushrooms?
Canada is strategizing to become a major player in the psychedelics market, mirroring its approach to cannabis. This could encourage more companies to produce high-quality products. As a result, Canada has the potential to establish itself as a leading player in the hallucinogen market, boost its economy, and enable other countries to access these treatments. It would also discourage other countries from procuring their hallucinogens from illegal dispensaries or suppliers, thereby ensuring safety.
Articles of Interest:
